Vorinostat in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

This study is ongoing, but not recruiting participants.

Study NCT00253630 Information provided by California Cancer Consortium

First Received: November 11, 2005 Last Updated: October 11, 2010 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study is ongoing, but not recruiting participants.
Estimated Study Completion Date:	No date given
Estimated Primary Completion Date:	February 2007 (Final data collection date for primary outcome measure)

Publications:

Kirschbaum M, Zain J, Popplewell L, et al.: Phase 2 study of suberoylanilide hydroxamic acid (SAHA) in relapsed or refractory indolent non-Hodgkin lymphoma: a California Cancer Consortium study. [Abstract] J Clin Oncol 25 (Suppl 18): A-18515, 703s, 2007.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Kirschbaum M, Frankel P, Popplewell L, Zain J, Delioukina M, Pullarkat V, Matsuoka D, Pulone B, Rotter AJ, Espinoza-Delgado I, Nademanee A, Forman SJ, Gandara D, Newman E. Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol. 2011 Mar 20;29(9):1198-203. Epub 2011 Feb 7.